Cancer

Article	Citations
Active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer	517
Issue Information	437
The economics of advanced and unresectable hepatocellular carcinoma	232
New standard of care for multiple myeloma?	174
Best of both worlds? Linking comprehensive and noncomprehensive cancer centers	170
MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis	148
Potential of circulating tumor DNA to refine immunotherapy	115
Serum of interleukin‐6 and procalcitonin as early diagnostic markers for the identification of poor hematopoietic reconstitution following allogeneic hematopoietic stem cell transplantation	95
Reply to “Enhancing the role of social work in managing cancer risks among LGBTQ+ populations” and “The urgency of systematically acquiring sexual orientation and gender identity data to ensure equity	85
	81
Accelerated approval of multiple myeloma therapies	79
	76
Issue Information	76
	74
Issue Information	72
Issue Information	71
	66
New test for detecting cervical adenocarcinoma	64
The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient‐centere	63
Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?	62
Stopping immunotherapy after 2 years is practical in patients with advanced non–small cell lung cancer	62
Sharp rise in esophageal cancer and Barrett esophagus seen in middle‐aged people	61
Development and validation of a machine‐learning–based pathomics nomogram for predicting recurrence of localized primary gastrointestinal stromal tumors after complete surgical resection: A retrospect	60
Updates on research and management of gastrointestinal stromal tumors in China	59
Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non‐Indigenous men in a universal health care system	58

What’s the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?	56
Midlife baseline prostate‐specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality	55
Erratum to “Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation”	51
Erratum to “Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study”	49
Updated American Cancer Society lung cancer screening guidelines	49
Erratum to “Unhealthy lifestyle behaviors, overweight, and obesity among childhood cancer survivors in the Netherlands: A DCCSS LATER study”	49
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia	49
Erratum to “Chimeric antigen receptor–based immunotherapy in breast cancer: Recent progress in China”	49
Correction to “Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly”	48
Epistemic equity in oncology: Opportunities to leverage patient‐centric implementation in clinical trial design	48
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53	48
What enhanced recovery means for patients with cancer undergoing surgery	45
Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders	45
Characteristics of clinical trials of new oncology drugs approved in China	45
Improved survival and decreased cancer deaths in young adults with cancer after passage of the Affordable Care Act Dependent Coverage Expansion	44
Redefining the “crown”: Approaching chemotherapy‐induced alopecia among Black patients with breast cancer	44
Risk scores predicting disease progression in early‐stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy	44
The role of relative advantage for development of sequencing‐based diagnostics for pediatric cancer in low‐ and middle‐income countries	43
Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana	43
Top advances of the year: Neoadjuvant immunotherapy in melanoma	42
Dietary supplement use among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study	42
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation	42
Meeting the moment: Addressing racial disparities in cancer survival	42
Aspirin but not statins is inversely related to gastric cancer with a duration–risk effect: Results from the Stomach Cancer Pooling Project Consortium	42
What are the most effective exercise, physical activity and dietary interventions to improve body composition in women diagnosed with or at high‐risk of breast cancer? A systematic review and network	41
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases	40
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3‐tyrosine kinase domain mutations: Prognostic implications of NPM1 co‐mutation	40
Top advances of the year: Cervical cancer	40
Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia	39
Occurrence of breast‐cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two‐arm randomized clinical trial	39
Understanding risk factors for cancer: What's new and how can it help reduce the cancer burden?	38
Association between visceral adiposity index and cancer risk in the UK Biobank cohort	38
Effect of an mHealth intervention on physical activity outcomes among young adult cancer survivors: The IMPACT randomized controlled trial	38
Patterns of failure in pediatric medulloblastoma and implications for hippocampal sparing	38
Implantable cardioverter defibrillators in people dying with cancer: A SEER‐Medicare analysis of ICD prevalence and association with aggressive end‐of‐life care	38
Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers	37
A guide to large data sets for population‐based cancer research: Strengths, limitations, and pitfalls	37
“Cancer Statistics, 2025” provides data on cancer occurrence and outcomes	37
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer	35
Unveiling the impact of chemotherapy in patients with breast cancer: A longitudinal study on peripheral inflammation, multimodal magnetic resonance imaging, and cognition	35
Recent histone deacetylase inhibitors in cancer therapy	35
Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries	35
Family characteristics and childcare patterns associated with early social functioning in cancer‐bereaved parents	34
Correction to “Health care discrimination and self‐reported health in transgender, gender nonconforming, and nonbinary individuals with cancer”	33
Breast cancer survival in India across 11 geographic areas under the National Cancer Registry Programme	32
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies	32
Adjuvant chemoradiation offers minimal survival improvements over radiation alone in intermediate‐risk, early cervical cancer	31
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG‐ACRIN analysis	31
Long‐term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial	31
Issue Information	31

Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”	30
Adherence to healthy dietary patterns and risk of premature aging in adult survivors of childhood cancer in the St. Jude Lifetime Cohort Study	30
Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?	30
Correction to “Retrospective analysis of cutaneous immune‐related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA‐B*51:01 alle	30
The protective role of postoperative radiation therapy in low and intermediate grade major salivary gland malignancies: A study of the Canadian Head and Neck Collaborative Research Initiative	30
Safety, efficacy, and pharmacokinetics of SH‐1028 in EGFR T790M‐positive advanced non–small cell lung cancer patients: A dose‐escalation phase 1 study	30
ESMO publishes guidance on use of AI‐based biomarkers in oncology	30
	29
Cervical cancer elimination in Indian context: Moving from barriers to facilitators	29
Utilization and perceptions of chaplaincy among hospitalized adults of Dharmic religions with cancer	29
Acute hospitalizations after proton therapy versus intensity‐modulated radiotherapy for locally advanced non–small cell lung cancer in the durvalumab era	29
Prospective associations between sleep quality and sexual satisfaction in distressed breast cancer survivors: Secondary analysis from the Apps Reaching Cancer Survivors randomized trial	29
Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression	29
	28
Standard of care for children with newly diagnosed B‐cell ALL	28
Making a case for del(1p) as a high‐risk abnormality in multiple myeloma	28
	28
Helping patients with cancer to understand secondary findings on genetic tests	28
From childhood cancer to metabolic syndrome	28
Immune check point inhibitors in advanced cutaneous squamous cell carcinomas: “Repeat and replicate”	27
Clinical implications of tumor‐based next‐generation sequencing in high‐grade epithelial ovarian cancer	27
	27
Anti‐Müllerian hormone for assessing ovarian toxicity of cancer treatment in young women: It’s complicated	27
Issue Information	27
Lost in the shadow of giants: The neglected treatment modalities in oncologic trials	27
Diabetes mellitus and neurocognition: A report from the Childhood Cancer Survivor Study	27
Continuity and coordination of care for childhood cancer survivors with multiple chronic conditions: Results from the Childhood Cancer Survivor Study	26
The American Cancer Society National Lung Cancer Roundtable strategic plan: Introduction	26
Integrating systemic therapy into larynx preservation: Lessons from 3 decades of progress	26
Physical fitness and clinically assessed disease burden in long‐term childhood cancer survivors—The SURfit study	26
Estimating oncologist variability in prescribing systemic cancer therapies to patients in the last 30 days of life	26
Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial	26
Beyond the PSA: The hidden costs of screening in prostate cancer	26
The safety of trastuzumab deruxtecan (T‐DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta‐analysis	25
Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver disease	25
Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer	25
Patterns of lung cancer incidence in adults diagnosed under age 50 in the United States, 2000–2021	25
Early time of day of administration of immunochemotherapy for enhancing overall survival in patients with lung cancer irrespective of histological type?	25
Landscape and clinical impact of NOTCH mutations in newly diagnosed acute myeloid leukemia	25
Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT–confirmed complete response	25
Breast cancer staging for patients with “low‐risk” disease: Are they all the same?	25
Associations between experiences of discrimination and quality of life in Black breast cancer survivors	24
Most older patients with advanced cancer prioritize QOL over extending survival	24
Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study	24
Breast cancer trends in China and its comparative analysis with group of 20 countries: Projections for 2022–2040	24
A randomized prospective trial of an ostomy telehealth intervention for cancer survivors	24
Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS‐5	24
	24
“Protected time” for clinical investigators in medical oncology: The persistent gap between expectation and reality	24
Triple‐negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding	24
Exercise recommendations for older adults living with and beyond cancer: A consensus statement by the Advancing Capacity to Integrate Exercise Into the Care of Older Cancer Survivors expert panel	24
Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer	23
A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers	23
The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance	23
Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute lymphoblastic leukemia: A multicente	23
Effect of preoperative programmed death‐1 or programmed death ligand‐1 immune check point inhibition on complications after surgery for primary head and neck cancer	23
Associations between geography, decision‐making style, and interest in cancer clinical trial participation	23
Civic engagement and breast cancer screening participation among US citizens	23
Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact	23
Real‐world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia	22
Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions	22
Valued Living intervention to increase advance care planning and well‐being in depressed and anxious adults with advanced cancer: Randomized trial in community oncology clinics	22
A call to action to advance patient‐focused and decentralized clinical trials	22
Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 tri	22
Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial	22
Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study	22
Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors	22
Burden of female‐specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021	21
Associations of serum trimethylamine N‐oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort	21
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing?	21
Oncologists’ role in end‐of‐life chemotherapy and patient‐centered care	21
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study	21
Effects of exercise therapy on chemotherapy delivery and response in primary breast cancer: A secondary analysis of a randomized trial	21
Primary osteosarcoma of the ribs: A report from the Cooperative Osteosarcoma Study Group	21
AACR 2024 presents advancements in pancreatic and gastric cancers	21
Impact of acupuncture and integrative therapies on chemotherapy‐induced peripheral neuropathy: A multicentered, randomized controlled trial	21
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry	21
Top advances of the year: Targeted therapy for lung cancer	21
First person profile: Robert C. Bast Jr MD	21
Reasons for refusal of the human papillomavirus vaccine among young cancer survivors	21

Cyclin‐dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple‐negative breast cancer by affecting the immune microenvironment	20
EGFR exon 20–targeting sunvozertinib granted accelerated approval for advanced NSCLC	20
Erratum to “Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children’s Oncology Group”	20
Gaps in care highlight the need to expand access to clinical cancer trials	20
Targeted genotyping for recurring variants in cancer susceptibility genes in non‐Ashkenazi Jewish patients with breast cancer diagnosed ≥50 years	20
Palliative care training can help patients with advanced cancer at the end of life	20
Breast health equity along the cancer care continuum: A collaborative grant initiative	20
Stage I epithelial or stromal type Wilms tumors are low risk tumors: An analysis of patients treated on the SIOP‐WT‐2001 protocol in the UK‐CCLG and GPOH studies (2001–2020)	20
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago‐gastric Diseases (PROCEED): A single‐arm phase 2 trial	20
Issue Information	20
Issue Information	20
Hepatocellular carcinoma, vascular endothelial growth factor receptors‐targeting agents, and hypertension: A much more complicated relationship than expected	20
Geographic diffusion of digital mammography in the United States	20
Factors associated with prostate cancer screening among Hispanic men: Results from the Hispanic Community Health Study/Study of Latinos	20
Comparison of survival outcomes for patients with Stage III vs de novo Stage IV breast cancer	20
	20
Safety and promising efficacy with enhanced CAR T‐cell therapy for lymphoma	20
Nomogram predicts survival and surgical benefits for patients with breast cancer with initial bone metastasis: A population‐based study	20
Second‐line chimeric antigen receptor T‐cell therapy versus standard of care in relapsed or refractory large B‐cell lymphoma: A systematic review and meta‐analysis	19
A phase 1 study of berzosertib (M6620, VX‐970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)	19
Multidimensional structural racism and estimated cancer risk from traffic‐related air pollution	19
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study	19
Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology	19
The relationship of mental health symptoms to chemotherapy toxicity risk in older adults with cancer: Results from the geriatric assessment–driven intervention study	19
Endoscopic balloon cryoablation plus transurethral resection for bladder cancer: A phase 2, multicenter, randomized, controlled trial	19
The American Cancer Society National Lung Cancer Roundtable strategic plan: Tobacco treatment in the context of lung cancer screening	19
Neoadjuvant therapy for patients with nonsmall cell lung cancer: Not as easy in the real world	19
Issue Information	19
A prospective study on diagnostic accuracy of technology‐enabled early detection of oral cancer and epidemiology of tobacco and other substances use in rural India	19
Assessment of the compliance, influencing factors, and yielding results of liver cancer screening in a high‐risk population: A cross‐sectional study	19
Is repeat breast conservation possible for small ipsilateral breast cancer recurrence?	19
Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters	19
Emerging role of antibody–drug conjugates in gastrointestinal malignancies	19
Reply to “Comments on chemoradiotherapy in IDH wild‐type/TERT‐mutant grade 2/3 gliomas”	19
Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study	19
Cannabis use among adults undergoing cancer treatment	19
Cumulative incidence and risk factors of brain metastases in metastatic non–small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IM	19
Implementation and evaluation of a remote geriatric assessment and intervention program in Brazil	19
Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients	19
Determinants of geographic variation in the incidence of adult nonmalignant meningioma in the United States, 2010–2019	19
Not all progression is equal	19
An editorial on a comparison of care quality metrics between Black and White men with advanced prostate cancer in the IRONMAN registry	19
First person profile: Julie Brahmer, MD	18
Cytokine release syndrome in solid tumors	18
Cancer survivors have an increased risk of cardiovascular disease	18
Potential new standard of care for the first‐line treatment of metastatic colorectal cancer	18
	18
	18
	18
Genomics likely are not the main driver in advanced prostate cancer overall survival rate disparities	18
Issue Information	18
A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas	18
	18
Cancer registries: A look back and forward	18
Issue Information	18
A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies	18
When destiny doesn’t pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan	17
Sexual health in adult survivors of childhood cancer: A Project REACH study	17
Issue Information	17
Chronic conditions, cancer disparities, and the unique needs of Black women with ovarian cancer	17
Impact of resistance training on inflammatory biomarkers and associations with treatment outcomes in colon cancer	17
Frequency and face validity of reported family history of cancer in first‐degree relatives and genetic syndromes among children with cancer in Project:EveryChild: A report from the Children’s Oncology	17
Bariatric surgery and oral chemotherapy: Where is the dosing guidance?	17
Glucose‐6‐phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine	17
Delineation of features, responses, outcomes, and prognostic factors in pediatric PDGFRB‐positive acute lymphoblastic leukemia patients: A retrospective multicenter study	17
Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE)	17
Parents’ and adolescents’ perspectives and understanding of information about childhood cancer precision medicine	17
Caring for caregivers in early‐phase clinical oncology trials	17
Systemic therapies at the end of life vary by patient and practice	17
Issue Information	17
Provider motivations and barriers to cancer clinical trial screening, referral, and operations: Findings from a survey	17
Top advances of the year: Palliative and supportive care in oncology	17
Electronic health intervention to manage symptoms of immunotherapy in patients with cancer (SOFIA): Results from a randomized controlled pilot trial	17
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation	17
Historical redlining and survival among children, adolescents, and young adults with cancer diagnosed between 2000–2019 in Seattle and Tacoma, Washington	17
Issue Information	17
	17
Correction to “Hematopoietic effects of tagraxofusp in treatment‐naive patients with blastic plasmacytoid dendritic cell neoplasm”	17
Meta‐analysis of sex and racial subgroup participation rates and differential treatment effects for trials in solid tumor malignancies leading to US Food and Drug Administration registration between 2	17
Sun protection and skin cancer screening after childhood cancer—A report from the Swiss Childhood Cancer Survivor Study	17
American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines	16
The evolving therapeutic revolution in adult acute lymphoblastic leukemia	16
Efficacy of losartan plus modified FOLFIRINOX versus modified FOLFIRINOX in advanced pancreatic cancers: A randomized clinical trial (AFPAC Study)	16
Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high‐risk prostate cancer: A predictive biomarker analysis	16
Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality	16
Cancer incidence in the US military: An updated analysis	16
Top advances of the year: Cervical cancer	16
Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors	16
Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study	16
Associations between birth defects with neural crest cell origins and pediatric embryonal tumors	16
The weight of the enemy: Tumor burden as a tumor‐agnostic prognostic marker and the limits of immunotherapy	16
First‐line CDK4/6 inhibitors fail to improve overall survival in advanced breast cancer	16
Physical activity linked to decreased cancer‐related fatigue in patients with CRC	16
Correction to “Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus‐related liver cirrhosis”	16
Cumulative exposure to impaired fasting glucose and gastrointestinal cancer risk: A nationwide cohort study	16